4. "Full Market Awareness" A professional relations company and consulting firm Contact: Sean McDonald Direct: 941.208.3919 smcdonald@acornmanagementpartners.com Atlanta,Georgia & Sarasota,Florida Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISEMENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed before making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers make no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harbor Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in any and/or all profile/ research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various fa ctors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predictions, expectat ions, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stat ements in this action may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by compan ies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its web s ite.

2. Continue Reading for Investment Highlights, Recent News and Our Disclosure ... Platform Technology: VTS - Vascular Targeting System Ofra-vec uses a dual mechanism of action, which combines vascular disruption with induction of local anti-tumor immune response • Ongoing blinded, Phase 3 study (OVAL) has completed enrollment in Ph.3 • Ongoing recurrent GBM and colorectal cancer, Phase II trial s with data expected in 2022 MTT - Monocyte Targeting System VB-601 antibody offers a novel way to target monocytes/macrophages, a crucial cell in the inflammation triangle • Human proof-of-concept demonstrated using blood samples from patients with chronic inflammatory diseases, validating pre-clinical data " NOVEL TARGETED INVESTIGATIONAL THERAPIES TRANSFORMING THE WAY WE ADDRESS SOLID TUMORS AND INFLAMMATORY DISEASE " Analyst Coverage • GUGGENHEIM SEC. • H C WAINWRIGHT • OPPENHEIMER HLD • ROTH CAPITAL PA • JONES TRADING Differentiated Platform Technologies • Gene-based platform technology which enables targeting tumor vasculature and recruit ment of the immune system into tumors o MOST ADVANCED PROGRAM in PHASE 3 • Antibody platform targeting monocytes - for inflam m ation o MOST ADVANCED PROGRAM expe c ted to be in clinic in 2H22

3. Continue Reading for Our Disclosure Notice... Recent News: • VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May o IMMUNOLGY2022TM | Date: Sunday, May 8th, 2022 o LifeSci Immunology & Inflammation Symposium | Date: Wednesday, May 11th, o Biomed Israel 2022 Conference | Date: Thursday, May 12th, 2022 o H.C. Wainwright Global Investment Conference | Date: Monday, May 23rd -Thursday, May 26th, 2022 • VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer • VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update o OVAL top-line data for O fra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 o Completed patient enrollment in the 409 patient OVAL Phase 3 registration enabling trial investigating ofra-vec in patients with platinum-resistant ovarian cancer o Preliminary data from ofra-vec Phase 2 trials in mCRC and rGBM expected in 2022 o VB-601, inflammatory disorders, expected to enter the clinic in 2H 2022 Investment Highlights: • • • Late Stage Opportunity Disruptive Technologies Broad Market Potential Multiple Upcoming Catalysts • 2 0 2 2 2 0 2 3 Preliminary data from NCI- sponsored Phase 2 study in colorectal cancer 2022 Topline PFS primary endpoint Data* 3Q22 Potential BLA filing with PFS data 1H23 Preliminary data from investigator-sponsored Phase 2 study of ofra-vec in rGBM 2022 Topline Overall Survival primary endpoint Data* 2023 * DSMC review 1Q22 Completion of recruitment 1Q22

1. AMP Quick Facts Vascular Biogenics Ltd. (Nasdaq G M: VBLT ) Acorn Management Partners, LLC July 2022 Nasdaq: VBLT Price: $ 1 .91 Date: 06 / 01 / 20 2 2 Fiscal Year: 12/31 MKT Cap: ~ $ 131.76 m C.O.H*: ~ $ 44.47 m Inside Ownership: ~ 23.95 % S/O*: ~ 69.35 m Float: ~ 46.42 m AVG Vol.: ~ 177.79 k Industry: Healthcare Biotechnology "Gene-based Biologics" * As of most recent filing Continue Reading for More Information, Recent News, Management Background & Our Disclosure... VBL Therapeutics VBL Therapeutics is a late clinical stage biotech company committed to the discovery, development and commercialization of next-generation, targeted medicines for malignant solid tumors and immune- or inflammatory indications. Market Opportunity VBL Therapeutics has the potential to address many solid tumors and therefore it is reasonable to assume that the applicability of the Ofra-vec platform with be broad based. Significant Milestones Expected in 2022 Institutional Ownership: ~ 20.48 % VBL Therapeutics, l ead oncology candidate, ofra-vec, is currently being evaluated in our oval phase 3 registration- enabling clinical trial in ovarian cancer. Readout of O val Progression Free Survival, co-primary endpoint , is expected in the third quarter of 2022. The goal is to develop and provide safe, effective and life- improving medicines to people living with cancer and immune-inflammatory diseases  Enrollment is complete OVAL registration-enabling Phase 3 study evaluating ofra-vec in ovarian cancer  Preliminary data from O fra- vec Phase 2 trials in colon cancer and GBM  Entering the clinic with VB-601 in inflammatory applications • (2H22)  Readout of progression-free survival from the Phase 3 OVAL study (2H22) Overall Survival (2023)